EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer
Background: Lung cancer is the leading cause of brain metastases (BM). The identification of driver oncogenes and matched targeted therapies has improved outcome in non-small cell lung cancer (NSCLC) patients; however, a better understanding of BM molecular biology is needed to further drive the pro...
Main Authors: | Pascale Tomasini, Cindy Serdjebi, Nataliya Khobta, Philippe Metellus, L’Houcine Ouafik, Isabelle Nanni, Laurent Greillier, Anderson Loundou, Frederic Fina, Celine Mascaux, Fabrice Barlesi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-12-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/17/12/2132 |
Similar Items
-
EGFR and KRAS mutation coexistence in lung adenocarcinomas
by: Vitor Manuel Leitão de Sousa, et al.
Published: (2015-04-01) -
Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
by: Omer Bayrak, et al.
Published: (2014-08-01) -
Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
by: Shen Shanxiang, et al.
Published: (2012-05-01) -
A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
by: Silvia Moreno, et al.
Published: (2021-04-01) -
Response rate of patients with baseline brain metastases from recently diagnosed non‐small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status
by: Oscar Arrieta, et al.
Published: (2020-04-01)